The following amendments have been made to the 'Update to Faron's Financial Calendar for
2024' announcement released on 27 February 2024 at 1:00 p.m.
EST / 6:00 p.m. GMT / 8:00 p.m. EET under RNS No
6663E.
- Replacement wording
included.
- Change of date of the Company's AGM and
publication of 2023 financial statement.
- Reasoning for change of date of publishing
financial statement release for the full year 2023 and Annual
Report 2023, including financial statements for the full
year.
- Wording on defined terms.
All other details remain unchanged.
The full amended text is shown below.
Faron Pharmaceuticals
Oy
("Faron" or "Company")
Replacement - Update to
Faron's Financial Calendar for 2024
Company announcement February 28, 2024,
at 4:00 p.m. GMT / 6:00 p.m. EET
TURKU, FINLAND / BOSTON, MA - February 28,
2024 - Faron
Pharmaceuticals Oy (AIM: FARN, First North: FARON), a clinical
stage biopharmaceutical company focused on tackling
difficult-to-treat cancers and inflammation via precision
immunotherapy, today announces an update to
its financial reporting calendar for 2023, further to the
announcement on December 22, 2023. This announcement replaces the
previous one dated February 27, 2024.
The Company's financial statement
release for the full year 2023 and Annual Report 2023, including
financial statements for the full year, will now be published on
March 13, 2024, at 2:00 a.m. EST
/ 07:00 a.m. GMT / 09:00 a.m. EET,
rather than on Thursday, February 29, 2024, as had been previously
communicated.
The publication date of Tuesday,
August 27, 2024, for Faron's half-year financial report for the
period January 1 to June 30, 2024, remains unchanged. The Company's
Annual General Meeting is planned to be convened on Friday, April
5, 2024.
A separate stock exchange notice
will be issued by Faron's board of directors to convene the
meeting.
The financial calendar has been
amended as a consequence of the breach of the Funding Agreement
between IPF and Faron, announced on February 19, 2024. As such, the
Board has been unable to approve the accounts for the full year
2023 for publication.
Full
Year Results Virtual Briefing
Following publication of Faron's
financial statement release for the full year 2023 on March 13,
2024, Dr. Markku Jalkanen, Chief Executive Officer, and James
O'Brien, Chief Financial Officer, will host a virtual briefing and
Q&A session for analysts on the day at 2:00 p.m. EET / 12:00
p.m. GMT (noon). Presentation link https://faron.videosync.fi/q4-2023
The full year results press release
for 2023, presentation, virtual briefing webcast details, and
Annual Report 2023 will be made available at
www.faron.com/investors.
A replay of the analyst briefing will be made available shortly
afterwards.
For more details about the analyst
briefing, please contact Faron@consilium-comms.com.
Capitalised terms used in this
announcement shall, unless otherwise defined, have the same
meanings as set out in the Company's announcement of February 19,
2024.
For
more information please contact:
Investor Contact
LifeSci Advisors
Daniel Ferry
Managing Director
daniel@lifesciadvisors.com
+1 (617) 430-7576
ICR
Consilium
Mary-Jane Elliott, David Daley,
Lindsey Neville
Phone: +44 (0)20 3709 5700
E-mail: faron@consilium-comms.com
Cairn Financial Advisers LLP, Nomad
Sandy Jamieson, Jo Turner
Phone: +44 (0) 207 213
0880
Peel Hunt LLP, Broker
Christopher Golden, James
Steel
Phone: +44 (0) 20 7418
8900
Sisu Partners Oy, Certified Adviser on Nasdaq First
North
Juha Karttunen
Phone: +358 (0)40 555 4727
Jukka Järvelä
Phone: +358 (0)50 553 8990
About Faron Pharmaceuticals Ltd
Faron (AIM: FARN, First North:
FARON) is a global, clinical-stage biopharmaceutical company,
focused on tackling cancers via novel immunotherapies. Its mission
is to bring the promise of immunotherapy to a broader population by
uncovering novel ways to control and harness the power of the
immune system. The Company's lead asset is bexmarilimab, a novel
anti-Clever-1 humanized antibody, with the potential to remove
immunosuppression of cancers through targeting myeloid cell
function. Bexmarilimab is being investigated in Phase I/II clinical
trials as a potential therapy for patients with hematological
cancers in combination with other standard treatments
treatments and as a monotherapy in last line solid
cancers. Further information is available
at www.faron.com.